Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the crystal study

The authors are commenting the article entitled “Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the Crystal study” published by Larsen et al. in Ophthalmology Retina 2018;2(2):134-142. The conclusion resulting from this article is that regardless of the antiangiogenic agents chosen (e.g., bevacizumab/ranibizumab), the treatment paradigms used (e.g., treat-and-extend/pro re nata/fixed-interval/escalated algorithm), the patient age, the baseline best-corrected visual acuity, and the form of central retinal vein occlusion (ischemic/nonischemic occlusion), the efficacy of treatment depends primarily on the promptness of the therapy after the onset of the retinal vein occlusion.